Ordastobart
Based on 1 Customer Validation
Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4+ and CD8+ T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98%
- CAS 番号: 2708115-83-5
- 分子量:128.96 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Orexin Receptor (OX Receptor) アイソフォーム固有の製品をすべて表示
More
生物活性
[G1 VH-VH-VH-h-CH2-CH3]-dimer
Human
TNFRSF4/OX40/CD134
Ordastobart (5-25 nM, 1 h at 37°C) induces high clustering of the OX40 receptor in CHO cells expressing a human OX40 extracellular domain coupled to GFP[1].
Ordastobart (0.001-1000 nM, 96 h) stimulates CD4+ and CD8+ cells enriched from PBMC[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CHO cells expressing a human OX40 extracellular domain coupled to GFP
-
Concentration:5, 25 nM
-
Incubation Time:1 h at 37°C
-
Result:Enhanced high-level co-occurrence of GFP (green) and AF647 (magenta) on the cell membrane.
-
Cell Line:CD4+ and CD8+ T cells enriched from healthy donor peripheral blood mononuclear cells (PBMC)
-
Concentration:0.001, 0.01, 0.1, 1, 10, 100, 1000 nM
-
Incubation Time:96 h at 37°C
-
Result:Increaseed human leukocyte antigen (HLA)-DR expression, with maximum activity reaching a peak between 0.1-10 nM and declining at concentrations above 10 nM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MCA-205 (C57BL/6) or CT26 (BALB/c) tumor-bearing (106) mice (6-8 weeks old, female) model[1]
-
Dosage:10 µg/single dose
-
Administration:i.v.
-
Result:Demonstrated good tolerability, reduced tumor size, and significantly improved survival.
Engaged and activated CD8+ T cells to control tumor growth.
Expanded CD8+ T cells within tumors and increases T cell frequency and proliferation within LNs; reduces CD8+ T cell frequency in tdLNs but increases proliferation Ki-67.
Increased CD4+ Teff proliferation as compared with controls, enhanced interferon (IFN)-γ and TNF-α production.
Increased the frequency of CD8+ T cells and decreased the frequency of Tregs compared with controls.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
VH-VH-VH-h-CH2-CH3
ELISA, FACS, Functional assay
-
Loaded Ordastobart on ProA biosensor, can bind OX40/TNFRSF4 Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78189) with an affinity constant of 1.30E-10 M as determined in BLI assay.
化学情報
-
CAS 番号 2708115-83-5
-
性状 Liquid
-
分子量 128.96 kDa
-
Color Colorless to light yellow
-
SMILES
[Ordastobart]
-
別名
INBRX-106; ES-102
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Ordastobart 関連分類
HY-P991336 関連分類
Powered by Bioz